Three cannabis products attenuated oxaliplatin-induced peripheral neuropathy by inhibiting proteins that mediate oxaliplatin transport.

Abstract

Abstract Oxaliplatin induced peripheral neuropathy (OIPN) has greatly limited its clinical application. The aim of this study was to investigate whether three plant cannabinoid products could reduce OXA-induced peripheral neurotoxicity by selectively inhibiting OXA uptake transporter expression. The results showed that the three cannabinoid products with CBD as the main component could effectively inhibit the expression of transporter OCT2/OCTN1/OCTN2, thereby reducing the platinum content in DRG and inhibiting OIPN. And promote the anti-tumor effect of OXA. Among them, full spectrum CBD containing 0.3%THC and other secondary cannabinoids has the most significant therapeutic effect, and the safe therapeutic dose range is wider. These results suggest that CBD down-regulates the expression of OXA transporter and inhibits the main component of OIPN. The addition of THC and other secondary cannabinoids can overcome the dose limitation of purified CBD and exert more significant therapeutic effect in synergy with CBD.